Skip to content
Next results · Q4 2026Projected

Mar 18, after the close

Thu, Mar 18, 2027in 121 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 25 – Mar 25

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$42.47M
Revenue, change from a year earlier: Q3 2026 −72.6%, Q2 2026 +38.9%, Q1 2026 −12.8%, Q4 2025 +477.3%
Net income
$22.09M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Results day

Typical moveA typical move of 3.2% either way

Up after 4 of 12, down after 8.

The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: +12.3% after Q2 2026.

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

When it reports

Usual day
Thursday
6 of its last 8
Session
after the close
After quarter end
37 to 78 days
10-Q filed
37 to 43 days
over its last 8
10-K filed
59 to 81 days
over its last 8

Based on 8 prior 10-K filings.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR